[1]Ivanov II. Microbe hunting hits home\[J\]. Cell Host Microbe,2017,21(3):282-285.
[2]Thursby E, Juge N. Introduction to the human gut microbiota\[J\]. Biochem J,2017,474(11):1823-1836.
[3]Brown EM, Kenny DJ, Xavier RJ. Gut microbiota regulation of T cells during inflammation and autoimmunity\[J\]. Annu Rev Immunol,2019,37:599-624.
[4]Duerkop BA, Vaishnava S, Hooper LV. Immune responses to the microbiota at the intestinal mucosal surface\[J\]. Immunity,2009,31(3):368-376.
[5]Hugon P, Dufour JC, Colson P, et al. A comprehensive repertoire of prokaryotic species identified in human beings\[J\]. Lancet Infect Dis,2015,15(10):1211-1219.
[6]Iliev ID, Leonardi I. Fungal dysbiosis: immunity and interactions at mucosal barriers\[J\]. Nat Rev Immunol,2017,17(10):635-646.
[7]Schmidt TSB, Raes J, Bork P. The human gut microbiome: from association to modulation\[J\]. Cell,2018,172(6):1198-1215.
[8]Blander JM, Longman RS, Iliev ID, et al. Regulation of inflammation by microbiota interactions with the host\[J\]. Nat Immunol,2017,18(8):851-860.
[9]Louis P, Hold GL, Flint HJ. The gut microbiota, bacterial metabolites and colorectal cancer\[J\]. Nat Rev Microbiol,2014,12(10):661-672.
[10]Vinolo MA, Rodrigues HG, Nachbar RT, et al. Regulation of inflammation by short chain fatty acids\[J\]. Nutrients,2011,3(10):858-876.
[11]Koh A, De Vadder F, KovatchevaDatchary P, et al. From dietary fiber to host physiology: shortchain fatty acids as key bacterial metabolites\[J\]. Cell,2016,165(6):1332-1345.
[12]Schulthess J, Pandey S, Capitani M, et al. The short chain fatty acid butyrate imprints an antimicrobial program in macrophages\[J\]. Immunity,2019,50(2):432-445.
[13]Steinert RE, Lee YK, Sybesma W. Vitamins for the gut microbiome\[J\]. Trends Mol Med,2020,26(2):137-140.
[14]HeintzBuschart A, Wilmes P. Human gut microbiome: function matters\[J\]. Trends Microbiol,2018,26(7):563-574.
[15]Lee N, Kim WU. Microbiota in Tcell homeostasis and inflammatory diseases\[J\]. Exp Mol Med,2017,49(5):e340.
[16]MullineauxSanders C, Suez J, Elinav E, et al. Sieving through gut models of colonization resistance\[J\]. Nat Microbiol,2018,3(2):132-140.
[17]Loomba R, Seguritan V, Li W, et al. Gut microbiomebased metagenomic signature for noninvasive detection of advanced fibrosis in human nonalcoholic fatty liver disease\[J\]. Cell Metab,2019,30(3):607.
[18]Kuang Z, Wang Y, Li Y, et al. The intestinal microbiota programs diurnal rhythms in host metabolism through histone deacetylase 3\[J\]. Science,2019,365(6460):1428-1434.
[19]Mowat AM, Agace WW. Regional specialization within the intestinal immune system\[J\]. Nat Rev Immunol,2014,14(10):667-685.
[20]Belkaid Y, Harrison OJ. Homeostatic immunity and the microbiota\[J\]. Immunity,2017,46(4):562-576.
[21]Rooks MG, Garrett WS. Gut microbiota, metabolites and host immunity\[J\]. Nat Rev Immunol,2016,16(6):341-352.
[22]Cheng H, Guan X, Chen D,et al. The Th17/Treg cell balance: a gut microbiotamodulated story\[J\]. Microorganisms,2019,7(12):583.
[23]Shale M, Schiering C, Powrie F. CD4+Tcell subsets in intestinal inflammation\[J\]. Immunol Rev,2013,252(1):164-182.
[24]Luo A, Leach ST, Barres R, et al. The microbiota and epigenetic regulation of T helper 17/regulatory T cells: in search of a balanced immune system\[J\]. Front Immunol,2017,8:417.
[25]Furusawa Y, Obata Y, Hase K. Commensal microbiota regulates T cell fate decision in the gut\[J\]. Semin Immunopathol,2015,37(1):17-25.
[26]GevaZatorsky N, Sefik E, Kua L, et al. Mining the human gut microbiota for immunomodulatory organisms\[J\]. Cell, 2017, 168(5):928-943.
[27]Furusawa Y, Obata Y, Fukuda S, et al. Commensal microbederived butyrate induces the differentiation of colonic regulatory T cells\[J\]. Nature,2013,504(7480):446-450.
[28]Tan TG, Sefik E, GevaZatorsky N, et al. Identifying species of symbiont bacteria from the human gut that, alone, can induce intestinal Th17 cells in mice\[J\]. Proc Natl Acad Sci U S A,2016,113(50):E8141-E8150.
[29]Round JL, Lee SM, Li J, et al. The Tolllike receptor 2 pathway establishes colonization by a commensal of the human microbiota\[J\]. Science,2011,332(6032):974-977.
[30]Crosby CM, Kronenberg M. Tissuespecific functions of invariant natural killer T cells\[J\]. Nat Rev Immunol,2018,18(9):559-574.
[31]Matsuda JL, Mallevaey T, ScottBrowne J, et al. CD1drestricted iNKT cells, the ‘SwissArmy knife’ of the immune system\[J\]. Curr Opin Immunol,2008,20(3):358-368.
[32]Narushima S, Sugiura Y, Oshima K, et al. Characterization of the 17 strains of regulatory T cellinducing humanderived Clostridia\[J\]. Gut Microbes,2014,5(3):333-339.
[33]Panduro M, Benoist C, Mathis D. Tissue Tregs\[J\]. Annu Rev Immunol,2016,34:609-633.
[34]Chen Z, Lin F, Gao Y, et al. FOXP3 and RORγt: transcriptional regulation of Treg and Th17\[J\]. Int Immunopharmacol,2011,11(5):536-542.
[35]Amatya N, Garg AV, Gaffen SL. IL17 signaling: the yin and the yang\[J\]. Trends Immunol,2017,38(5):310-322.
[36]Atarashi K, Tanoue T, Ando M, et al. Th17 cell induction by adhesion of microbes to intestinal epithelial cells\[J\]. Cell,2015,163(2):367-380.
[37]Omenetti S, Bussi C, Metidji A, et al. The intestine harbors functionally distinct homeostatic tissueresident and inflammatory Th17 cells\[J\]. Immunity,2019,51(1):77-89.
[38]Ravindran R, Loebbermann J, Nakaya HI, et al. The amino acid sensor GCN2 controls gut inflammation by inhibiting inflammasome activation\[J\]. Nature,2016,531(7595):523-527.
[39]Martinez GJ. MINK1: The missing link between ROS and its inhibition of Th17 cells\[J\]. J Exp Med,2017,214(5):1205-1206.
[40]Flannigan KL, Ngo VL, Geem D, et al. IL17Amediated neutrophil recruitment limits expansion of segmented filamentous bacteria\[J\]. Mucosal Immunol,2017,10(3):673-684.
[41]Sprouse ML, Bates NA, Felix KM, et al. Impact of gut microbiota on gutdistal autoimmunity: a focus on T cells\[J\]. Immunology,2019,156(4):305-318.
[42]Bradley CP, Teng F, Felix KM, et al. Segmented filamentous bacteria provoke lung autoimmunity by inducing gutlung axis Th17 cells expressing dual TCRs\[J\]. Cell Host Microbe,2017,22(5):697-704.
[43]Ueno A, Jeffery L, Kobayashi T, et al. Th17 plasticity and its relevance to inflammatory bowel disease\[J\]. J Autoimmun,2018,87:38-49.
[44]Mayer JU, Demiri M, Agace WW, et al. Different populations of CD11b+ dendritic cells drive Th2 responses in the small intestine and colon\[J\]. Nat Commun,2017,8:15820.
[45]Grencis RK. Immunity to helminths: resistance, regulation, and susceptibility to gastrointestinal nematodes\[J\]. Annu Rev Immunol,2015,33:201-225.
[46]Shimokawa C, Kato T, Takeuchi T, et al. CD8+ regulatory T cells are critical in prevention of autoimmunemediated diabetes\[J\]. Nat Commun,2020,11(1):1922.
[47]Atarashi K, Suda W, Luo C, et al. Ectopic colonization of oral bacteria in the intestine drives Th1 cell induction and inflammation\[J\]. Science,2017,358(6361):359-365.
[48]Ruiz L, Delgado S, RuasMadiedo P, et al. Bifidobacteria and their molecular communication with the immune system\[J\]. Front Microbiol,2017,8:2345.
[49]Gefen T, GevaZatorsky N. What came first: the microbiota or the Tr(egg) cells? \[J\]. Immunity,2018,48(6):1072-1074.
[50]Goto Y, Panea C, Nakato G, et al. Segmented filamentous bacteria antigens presented by intestinal dendritic cells drive mucosal Th17 cell differentiation\[J\]. Immunity,2014,40(4):594-607.
[51]Omenetti S, Pizarro TT. The Treg/Th17 axis: a dynamic balance regulated by the gut microbiome\[J\]. Front Immunol,2015,6:639.
[52]Gagliani N, Amezcua Vesely MC, Iseppon A, et al. Th17 cells transdifferentiate into regulatory T cells during resolution of inflammation\[J\]. Nature,2015,523(7559): 221-225.
[53]Patel DD, Kuchroo VK. Th17 cell pathway in human immunity: lessons from genetics and therapeutic interventions\[J\]. Immunity,2015,43(6):1040-1051.
[54]Ohnmacht C, Park JH, Cording S, et al. MUCOSAL IMMUNOLOGY. The microbiota regulates type 2 immunity through RORγt+ T cells\[J\]. Science,2015,349(6251):989-993.
[55]Clough JN, Omer OS, Tasker S, et al. Regulatory Tcell therapy in Crohn′s disease: challenges and advances\[J\]. Gut,2020,69(5):942-952.
[56]Britton GJ, Contijoch EJ, Mogno I, et al. Microbiotas from humans with inflammatory bowel disease alter the balance of gut Th17 and RORγt+ regulatory T cells and exacerbate colitis in mice\[J\]. Immunity,2019,50(1):212-224.
[57]Atarashi K, Tanoue T, Oshima K, et al. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota\[J\]. Nature,2013,500(7461):232-236.
[58]Dore MP, Rocchi C, Longo NP, et al. Effect of probiotic use on adverse events in adult patients with inflammatory bowel disease: a retrospective cohort study\[J\]. Probiotics Antimicrob Proteins,2020,12(1):152-159.
[59]Allegretti J, Eysenbach LM, ElNachef N, et al. The current landscape and lessons from fecal microbiota transplantation for inflammatory bowel disease: past, present, and future\[J\]. Inflamm Bowel Dis,2017,23(10):1710-1717.
[60]Gülden E, Wong FS, Wen L. The gut microbiota and Type 1 Diabetes\[J\]. Clin Immunol,2015,159(2):143-153.
[61]Endo Y, Yokote K, Nakayama T. The obesityrelated pathology and Th17 cells\[J\]. Cell Mol Life Sci,2017,74(7):1231-1245.
[62]Turnbaugh PJ, Ley RE, Mahowald MA, et al. An obesityassociated gut microbiome with increased capacity for energy harvest\[J\]. Nature,2006,444(7122):1027-1031.
[63]Garrett WS. Cancer and the microbiota\[J\]. Science,2015,348(6230):80-86.
[64]Chen D, Wu J, Jin D,et al. Fecal microbiota transplantation in cancer management: current status and perspectives\[J\]. Int J Cancer,2019,145(8):2021-2031.
[65]Amicarella F, Muraro MG, Hirt C, et al. Dual role of tumourinfiltrating T helper 17 cells in human colorectal cancer\[J\]. Gut,2017,66(4):692-704.
[66]Cremonesi E, Governa V, Garzon JFG, et al. Gut microbiota modulate T cell trafficking into human colorectal cancer\[J\]. Gut,2018,67(11):1984-1994.
[67]Wu HJ, Ivanov II, Darce J, et al. Gutresiding segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells\[J\]. Immunity,2010,32(6):815-827.
[68]Cekanaviciute E, Yoo BB, Runia TF, et al. Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models\[J\]. Proc Natl Acad Sci U S A,2017,114(40):10713-10718.
[69]Canavan JB, Scottà C, Vossenkmper A, et al. Developing in vitro expanded CD45RA+ regulatory T cells as an adoptive cell therapy for Crohn′s disease\[J\]. Gut,2016,65(4):584-594.
[70]Viaud S, Saccheri F, Mignot G, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide\[J\]. Science,2013,342(6161):971-976.
[71]Vétizou M, Pitt JM, Daillère R, et al. Anticancer immunotherapy by CTLA4 blockade relies on the gut microbiota\[J\]. Science,2015,350(6264):1079-1084.
[72]Zou W, Wolchok JD, Chen L. PDL1 (B7H1) and PD1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations\[J\]. Sci Transl Med,2016,8(328):328rv4.
|